Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 13/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7530327 | 0.91 | CACNA1B (0.73) | CACNA1BADORA3CACNA1CMEN1MAPT | |
| SCHEMBL5411001 | 0.90 | CACNA1B (0.78) | CACNA1BADORA3CACNA1FCACNA1DCACNA1S | |
| SCHEMBL5396621 | 0.89 | CACNA1B (0.71) | CACNA1BADORA3CACNA1CMEN1MAPT | |
| SCHEMBL7530458 | 0.87 | CACNA1B (1.00) | CACNA1B | |
| SCHEMBL7527518 | 0.86 | CACNA1B (0.72) | CACNA1BADORA3CACNA1CMEN1KMT2A | |
| SCHEMBL7527521 | 0.86 | CACNA1B (0.72) | CACNA1BADORA3CACNA1CMEN1KMT2A | |
| SCHEMBL4496949 | 0.86 | CACNA1B (0.67) | CACNA1BCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL7532340 | 0.86 | CACNA1B (0.87) | CACNA1BADORA3CACNA1FCACNA1DCACNA1S | |
| SCHEMBL7525350 | 0.86 | CACNA1B (0.71) | CACNA1BMEN1MAPTKMT2ATDP1 | |
| SCHEMBL4495941 | 0.83 | CACNA1B (0.69) | CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247645-B2 | Dihydropyridine derivatives | AJINOMOTO CO., INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-7247645-B2 | Dihydropyridine derivatives | AJINOMOTO CO., INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-7247645-B2 | Dihydropyridine derivatives | AJINOMOTO CO., INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20020147222-A1 | Dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-10-10 | — | — | US | disclosed |
| EP-1191021-A1 | DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147222-A1 | Dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | CACNA1B 1/4885ADORA3 1792/4885CACNA1F 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.